{"id":393888,"date":"2020-12-06T08:33:21","date_gmt":"2020-12-06T13:33:21","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=393888"},"modified":"2020-12-06T08:33:21","modified_gmt":"2020-12-06T13:33:21","slug":"cardiff-oncology-presents-data-at-ash-demonstrating-the-safety-and-anti-leukemic-activity-of-onvansertib-in-patients-with-relapsed-refractory-aml","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-presents-data-at-ash-demonstrating-the-safety-and-anti-leukemic-activity-of-onvansertib-in-patients-with-relapsed-refractory-aml\/","title":{"rendered":"Cardiff Oncology Presents Data at ASH Demonstrating the Safety and Anti-Leukemic Activity of Onvansertib in Patients with Relapsed\/Refractory AML"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SAN DIEGO<\/span>, Dec. 6, 2020<\/span> \/PRNewswire\/ — Cardiff Oncology, Inc. (Nasdaq:\u00a0CRDF)<\/b>, a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced the presentation of updated data from its Phase 1b<\/span>\/2 study in relapsed\/refractory acute myeloid leukemia (AML). The data were presented as a virtual oral poster presentation at the 62nd<\/sup> American Society of Hematology (ASH) Annual Meeting.<\/p>\n

\n

\n
\n \"Cardiff
\n <\/a>\n <\/p>\n<\/p><\/div>\n

The presentation highlighted the safety, tolerability and anti-leukemic activity of onvansertib in combination with decitabine in patients with difficult-to-treat relapsed\/refractory AML. Nine of 45 (20%) patients achieved a complete remission with or without hematologic count recovery (CR\/CRi \u2013 5 in Phase 1b<\/span> and 4 in Phase 2); 55% of responders had a mutation in a splicing factor. Two patients proceeded to transplant following CR and four patients remain on treatment with duration of response of 9, 10, 17 and 20 months, respectively. Together with data demonstrating the safety and tolerability of the combination therapy, these findings highlight onvansertib’s potential to address critical unmet needs in hematologic malignancies.<\/p>\n

“The data generated from this ongoing trial are encouraging, particularly considering the very poor prognosis of the relapsed\/refractory AML patient population, in whom the median overall survival is generally only a few months,” said Dr. Mark Erlander<\/span>, chief executive officer of Cardiff Oncology. “We believe the over-representation of the splicing factor mutations in patients who achieved a complete response is worthy of further exploration as it may provide a means for identifying patients upfront who have the greatest likelihood of responding to treatment with onvansertib.”<\/p>\n

Key data and conclusions from the ASH presentation include:<\/p>\n